VBIO — Malachite Innovations, Inc.
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: OTC
- Employees: 3
- Website: http://www.malachiteinnovations.com
Latest SEC filings for VBIO
- EFFECT — 2026-10-21
- EFFECT — 2026-10-21
- S-3 — 2026-10-16
- 8-K — 2026-09-01
- 8-K — 2026-08-27
- RW — 2026-08-24
- 8-K/A — 2026-08-20
- 8-K — 2026-08-18
- 8-K — 2026-08-17
- 10-Q — 2026-08-14
Latest VBIO news
- — A new system showed a strong link to a cell-growth measure during fermentation. Valion Bio plans further development. - Stock Titan (Stock Titan)
- — Valion Bio, Inc. Stock Price Today | VBIO Live Chart & News - Traders Union (Traders Union)
- — Valion Bio, Inc. (VBIO) Stock Price History & Data - Traders Union (Traders Union)
- — Valion Bio, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (VBIO) - Traders Union (Traders Union)
- — Live Valion Bio, Inc. (VBIO) Technical Analysis - Traders Union (Traders Union)
- — Some patented drug imports face taxes up to 100%. Valion offers U.S. biologic production. - Stock Titan (Stock Titan)
- — Valion Bio, Inc. (VBIO) Stock Price Prediction for 2026, 2030-2040 - Traders Union (Traders Union)
- — Valion Bio, Inc. (VBIO) Stock Price & News - Syfe (Syfe)
- — A potential radiation drug could be absorbed through the mouth instead of injected. - Stock Titan (Stock Titan)
- — Valion Bio Secures Additional Series B Preferred Financing - The Globe and Mail (The Globe and Mail)
Educational tool only — not investment advice.